Moreover, the inhibition of USP7 enzyme could be considered an ideal treatment, in combination with the PARP inhibitors, in both hormone-sensitive and androgen-resistant prostate tumors that express USP7 and CCDC6. Here, CCDC6 is linked to prostate neoplasm.